<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557583</url>
  </required_header>
  <id_info>
    <org_study_id>VBY-376-001</org_study_id>
    <nct_id>NCT00557583</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Sequential, Single Ascending Dose Evaluation of the Safety and Pharmacokinetics of VBY-376 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virobay Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virobay Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety and pharmacokinetics of single doses of VBY-376 in healthy
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single dose escalation study of 5 dose levels of VBY-376. Eight subjects per group will
      receive one dose of VBY-376 then have multiple blood draws for pharmacokinetic evaluation and
      followed for safety with laboratory evaluations, ECG's, vital signs, and adverse events.
      Safety data will be reviewed before proceeding to the next dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of VBY-376 in single oral doses in healthy subjects.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of VBY-376 after single oral doses and the effect of food on VBY-376.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">48</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBY 376</intervention_name>
    <description>Doses of 50mg and higher or placebo will be evaluated.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and females between 18 and 45 years of age

          -  screening body mass index between 20 and 29 kg/m2

          -  in good health with no clinically significant medical conditions

          -  able to comprehend and willing to sign an informed consent

        Exclusion Criteria:

          -  history of renal, hepatic impairment, stomach or intestinal surgery or resection,
             malabsorption syndrome

          -  anemia or blood donation within 8 weeks of check-in

          -  plasma donation within 4 weeks of check-in

          -  history of alcoholism or drug addiction within 1 year prior to check-in

          -  use of drugs of abuse

          -  no tobacco-containing products within 6 months of study

          -  participation of any clinical trial within 30 days

          -  history or presence of abnormal ECG

          -  no prescription or over-the-counter medications within 14 days of study and during the
             study

          -  history of Gilbert's syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen D Flach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance CRU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.virobayinc.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>December 27, 2013</last_update_submitted>
  <last_update_submitted_qc>December 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VBY-376 Hepatitis C pharmacokinetics safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

